Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 21, 2015

Primary Completion Date

June 16, 2018

Conditions
Nasopharyngeal Nonkeratinizing CarcinomaRecurrent Nasopharynx CarcinomaStage III Nasopharyngeal Carcinoma AJCC v7Stage IV Nasopharyngeal Carcinoma AJCC v7Stage IVA Nasopharyngeal Carcinoma AJCC v7Stage IVB Nasopharyngeal Carcinoma AJCC v7Stage IVC Nasopharyngeal Carcinoma AJCC v7
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (19)

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

33612

Moffitt Cancer Center, Tampa

55905

Mayo Clinic Cancer Center P2C, Rochester

Mayo Clinic, Rochester

60451

UC Comprehensive Cancer Center at Silver Cross, New Lenox

60611

Northwestern University, Chicago

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

90033

Los Angeles County-USC Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

91105

Keck Medical Center of USC Pasadena, Pasadena

95817

University of California Davis Comprehensive Cancer Center, Sacramento

119074

National University Hospital Singapore, Singapore

169610

National Cancer Centre, Singapore

308433

Johns Hopkins Singapore, Singapore

Unknown

Chinese University of Hong Kong-Prince of Wales Hospital, Shatin

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02339558 - Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer | Biotech Hunter | Biotech Hunter